Chapter 3 │ Page 110 53. Kadletz, L., et al., Evaluation of spheroid head and neck squamous cell carcinoma cell models in comparison to monolayer cultures. Oncol Lett, 2015. 10(3): p. 12811286. 54. Dasari, S. and P.B. Tchounwou, Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol, 2014. 740: p. 364-78. 55. Rabik, C.A. and M.E. Dolan, Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Reviews, 2007. 33(1): p. 9-23. 56. Mali, S.B., Role of Cold atmospheric plasma in cancer management. Oral Oncology Reports, 2024. 9: p. 100133. 57. Hu, H., et al., New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects. Biomedicine & Pharmacotherapy, 2023. 163: p. 114778. 58. Ogawa, T., et al., Novel mechanism of cisplatin resistance in head and neck squamous cell carcinoma involving extracellular vesicles and a copper transporter system. Head & Neck, 2024. 46(3): p. 636-650. 59. Siemer, S., et al., Profiling Cisplatin Resistance in Head and Neck Cancer: A Critical Role of the VRAC Ion Channel for Chemoresistance. Cancers (Basel), 2021. 13(19). 60. Bayat Mokhtari, R., et al., Combination therapy in combating cancer. Oncotarget, 2017. 8(23): p. 38022-38043. 61. Özdemir, D. and M. Büssgen, E ectiveness and cost-e ectiveness of combination therapy versus monotherapy in malignant melanoma. Journal of Pharmaceutical Policy and Practice, 2023. 16(1): p. 106. 62. Millen, R., et al., Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification. Med, 2023. 4(5): p. 290-310.e12. 63. Driehuis, E., et al., Patient-Derived Head and Neck Cancer Organoids Recapitulate EGFR Expression Levels of Respective Tissues and Are Responsive to EGFR-Targeted Photodynamic Therapy. J Clin Med, 2019. 8(11). 64. Driehuis, E., et al., Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. Cancer Discov, 2019. 9(7): p. 852-871. 65. Le Compte, M., et al., Single-organoid analysis reveals clinically relevant treatmentresistant and invasive subclones in pancreatic cancer. npj Precision Oncology, 2023. 7(1): p. 128. 66. Zhou, J., et al., Immunogenic cell death in cancer therapy: Present and emerging inducers. J Cell Mol Med, 2019. 23(8): p. 4854-4865. 67. Yamazaki, T., et al., Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death & Di erentiation, 2014. 21(1): p. 69-78. 68. Kiss, E., et al., Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner. Respir Res, 2020. 21(1): p. 120. 69. Pu, Y., et al., pERK-mediated IL8 secretion can enhance the migration, invasion, and cisplatin resistance of CD10-positive oral cancer cells. BMC Cancer, 2021. 21(1): p. 1283. 70. Levina, V., et al., Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer, 2008. 123(9): p. 2031-40.
RkJQdWJsaXNoZXIy MTk4NDMw